Dinko Franceschi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dinko Franceschi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ana M. Franceschi
Department of Radiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, NY
1 shared publication - Anat Biegon
Department of Radiology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794, USA
1 shared publication - Jade Basem
Stony Brook University
1 shared publication - Michael Clifton
Vascular and Interventional Radiology, University of Minnesota Medical Center, Minneapolis, MN 55455, USA
1 shared publication - Osama Ahmed
Department of Radiology, Population and Preventative Medicine, SUNY Stony Brook, Stony Brook, NY, USA
1 shared publication - Reza Dashti
Department of Neurological Surgery, Stony Brook University Hospital, NY (R.D.).
1 shared publication
Latest Publications
- Open Access
- 28 March 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 102
Extraneural metastases of glioblastoma: A case report and literature review
Background: Glioblastoma (isocitrate dehydrogenase [IDH]-wildtype, WHO Grade 4) is known to have a high recurrence rate with poor management of morbidity and mortality. Metastatic spread of glioblastomas is rare with extraneural osseous spread having been reported in under 100 cases. In this report, a case of glioblastoma with widespread extraneural metastatic lesions, including distal extremities, is presented. Case Description: A 70-year-old female presented with progressive word-finding difficulty and confusion. Brain magnetic resonance imaging (MRI) revealed a 5 × 7 cm left temporal solid and cystic mass with heterogenous contrast enhancement and significant surrounding edema. She underwent near-total tumor resection, and the pathological diagnosis was glioblastoma, (IDH-wildtype, WHO grade 4), with sarcomatous and primitive neuronal components. She received radiation therapy and temozolomide over 4 months. At 5 months postoperative, she presented with new bilateral lower extremity weakness and left facial droop. MRI and positron emission tomography scans revealed local recurrence and metastatic lesions to vertebrae, extremities, and lymph nodes. Conclusion: Previous research into rare glioblastoma bone metastases supports the theories of spread through hematogenous routes, surgical disruption, glymphatic system, and potential genetic susceptibility. However, no literature to date can adequately explain the distal limb metastases presented in this case, which shows the necessity for further understanding of this pathology.
- 28 March 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 102
Open AccessExtraneural metastases of glioblastoma: A case report and literature review
Background: Glioblastoma (isocitrate dehydrogenase [IDH]-wildtype, WHO Grade 4) is known to have a high recurrence rate with poor management of morbidity and mortality. Metastatic spread of glioblastomas is rare with extraneural osseous spread having been reported in under 100 cases. In this report, a case of glioblastoma with widespread extraneural metastatic lesions, including distal extremities, is presented. Case Description: A 70-year-old female presented with progressive word-finding difficulty and confusion. Brain magnetic resonance imaging (MRI) revealed a 5 × 7 cm left temporal solid and cystic mass with heterogenous contrast enhancement and significant surrounding edema. She underwent near-total tumor resection, and the pathological diagnosis was glioblastoma, (IDH-wildtype, WHO grade 4), with sarcomatous and primitive neuronal components. She received radiation therapy and temozolomide over 4 months. At 5 months postoperative, she presented with new bilateral lower extremity weakness and left facial droop. MRI and positron emission tomography scans revealed local recurrence and metastatic lesions to vertebrae, extremities, and lymph nodes. Conclusion: Previous research into rare glioblastoma bone metastases supports the theories of spread through hematogenous routes, surgical disruption, glymphatic system, and potential genetic susceptibility. However, no literature to date can adequately explain the distal limb metastases presented in this case, which shows the necessity for further understanding of this pathology.
- Open Access
- 30 April 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (5) , 725
Modulation of Secondary Cancer Risks from Radiation Exposure by Sex, Age and Gonadal Hormone Status: Progress, Opportunities and Challenges
Available data on cancer secondary to ionizing radiation consistently show an excess (2-fold amount) of radiation-attributable solid tumors in women relative to men. This excess risk varies by organ and age, with the largest sex differences (6- to more than 10-fold) found in female thyroid and breasts exposed between birth until menopause (~50 years old) relative to age-matched males. Studies in humans and animals also show large changes in cell proliferation rates, radiotracer accumulation and target density in female reproductive organs, breast, thyroid and brain in conjunction with physiological changes in gonadal hormones during the menstrual cycle, puberty, lactation and menopause. These sex differences and hormonal effects present challenges as well as opportunities to personalize radiation-based treatment and diagnostic paradigms so as to optimize the risk/benefit ratios in radiation-based cancer therapy and diagnosis. Specifically, Targeted Radionuclide Therapy (TRT) is a fast-expanding cancer treatment modality utilizing radiopharmaceuticals with high avidity to specific molecular tumor markers, many of which are influenced by sex and gonadal hormone status. However, past and present dosimetry studies of TRT agents do not stratify results by sex and hormonal environment. We conclude that cancer management using ionizing radiation should be personalized and informed by the patient sex, age and hormonal status.
- 30 April 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (5) , 725
Open AccessModulation of Secondary Cancer Risks from Radiation Exposure by Sex, Age and Gonadal Hormone Status: Progress, Opportunities and Challenges
Available data on cancer secondary to ionizing radiation consistently show an excess (2-fold amount) of radiation-attributable solid tumors in women relative to men. This excess risk varies by organ and age, with the largest sex differences (6- to more than 10-fold) found in female thyroid and breasts exposed between birth until menopause (~50 years old) relative to age-matched males. Studies in humans and animals also show large changes in cell proliferation rates, radiotracer accumulation and target density in female reproductive organs, breast, thyroid and brain in conjunction with physiological changes in gonadal hormones during the menstrual cycle, puberty, lactation and menopause. These sex differences and hormonal effects present challenges as well as opportunities to personalize radiation-based treatment and diagnostic paradigms so as to optimize the risk/benefit ratios in radiation-based cancer therapy and diagnosis. Specifically, Targeted Radionuclide Therapy (TRT) is a fast-expanding cancer treatment modality utilizing radiopharmaceuticals with high avidity to specific molecular tumor markers, many of which are influenced by sex and gonadal hormone status. However, past and present dosimetry studies of TRT agents do not stratify results by sex and hormonal environment. We conclude that cancer management using ionizing radiation should be personalized and informed by the patient sex, age and hormonal status.
- Open Access
- 13 August 2020
- Published by Springer Nature in Cureus
- Vol. 12 (8)
Incidental PET/CT Findings of Suspected COVID-19 in a Region of High Prevalence
We describe a case of suspected COVID-19 pneumonia in a 61-year-old male with known primary central nervous system diffuse large B-cell lymphoma (DLBCL) who underwent restaging PET/CT during the initial peak of infection of COVID-19 pneumonia within the New York region. At the time of his routine PET-CT to assess for disease progression, typical CT imaging features of COVID-19 pneumonia were identified. Upon further investigation, the patient was asymptomatic, and his infection status remained unknown. He was subsequently lost to follow-up with his COVID-19 status pending.
- 13 August 2020
- Published by Springer Nature in Cureus
- Vol. 12 (8)
Open AccessIncidental PET/CT Findings of Suspected COVID-19 in a Region of High Prevalence
We describe a case of suspected COVID-19 pneumonia in a 61-year-old male with known primary central nervous system diffuse large B-cell lymphoma (DLBCL) who underwent restaging PET/CT during the initial peak of infection of COVID-19 pneumonia within the New York region. At the time of his routine PET-CT to assess for disease progression, typical CT imaging features of COVID-19 pneumonia were identified. Upon further investigation, the patient was asymptomatic, and his infection status remained unknown. He was subsequently lost to follow-up with his COVID-19 status pending.